We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Radius (RDUS) Osteoporosis Drug Positive in Phase III Study
Read MoreHide Full Article
Radius Health, Inc. (RDUS - Free Report) announced positive data from the phase III ACTIVE study (Abaloparatide Comparator Trial In Vertebral Endpoints) on abaloparatide for the treatment of postmenopausal women suffering from osteoporosis.
Data from the study revealed that abaloparatide-SC (80 mcg), when dosed daily for 18 months, led to a significant reduction in the incidence of new vertebral and non-vertebral fractures in postmenopausal women with osteoporosis, compared to placebo. Results were published in the Journal of the American Medical Association (JAMA).
We remind investors that abaloparatide is currently under review in both the U.S. and the EU for the treatment of women with postmenopausal osteoporosis.
An opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for the marketing application is expected in late 2016 or in 2017. Meanwhile, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of Mar 30, 2017.
In addition, the company is developing abaloparatide-transdermal (abaloparatide-TD) for potential use as a treatment for osteoporosis.
As per information provided by the company in its press release, approximately two million osteoporotic fractures take place annually in the U.S. This number is likely to grow to three million by 2025.
According to the National Osteoporosis Foundation (NOF), an estimated 10 million individuals in the U.S., comprising eight million women and two million men, are affected by osteoporosis, while an estimated 44 million individuals have demonstrated low bone mass, placing them at high risk for osteoporosis.
Drugs currently approved to treat osteoporosis include Actonel, Fosamax and Forteo among others.
Radius Health currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector include Geron Corporation (GERN - Free Report) , Anika Therapeutics Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . Each of these stock sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Radius (RDUS) Osteoporosis Drug Positive in Phase III Study
Radius Health, Inc. (RDUS - Free Report) announced positive data from the phase III ACTIVE study (Abaloparatide Comparator Trial In Vertebral Endpoints) on abaloparatide for the treatment of postmenopausal women suffering from osteoporosis.
Data from the study revealed that abaloparatide-SC (80 mcg), when dosed daily for 18 months, led to a significant reduction in the incidence of new vertebral and non-vertebral fractures in postmenopausal women with osteoporosis, compared to placebo. Results were published in the Journal of the American Medical Association (JAMA).
RADIUS HEALTH Price
RADIUS HEALTH Price | RADIUS HEALTH Quote
We remind investors that abaloparatide is currently under review in both the U.S. and the EU for the treatment of women with postmenopausal osteoporosis.
An opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for the marketing application is expected in late 2016 or in 2017. Meanwhile, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of Mar 30, 2017.
In addition, the company is developing abaloparatide-transdermal (abaloparatide-TD) for potential use as a treatment for osteoporosis.
As per information provided by the company in its press release, approximately two million osteoporotic fractures take place annually in the U.S. This number is likely to grow to three million by 2025.
According to the National Osteoporosis Foundation (NOF), an estimated 10 million individuals in the U.S., comprising eight million women and two million men, are affected by osteoporosis, while an estimated 44 million individuals have demonstrated low bone mass, placing them at high risk for osteoporosis.
Drugs currently approved to treat osteoporosis include Actonel, Fosamax and Forteo among others.
Radius Health currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector include Geron Corporation (GERN - Free Report) , Anika Therapeutics Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . Each of these stock sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>